Cuộc họp Báo cáo Kết quả Kinh doanh Quý 1 Niên độ Tài chính 2027 của Beyond Air (XAIR): Xúc tác từ FDA, Triển vọng 8 triệu USD năm 2026
Doanh thu quý 1 năm tài chính 2027 của Beyond Air duy trì ở mức 1,8 triệu USD, biên lợi nhuận gộp tăng lên 13% và ban lãnh đạo tái khẳng định dự báo 8 triệu USD cho năm dương lịch 2026.
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.